{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Psoriasis+Vulgaris",
    "query": {
      "condition": "Psoriasis Vulgaris"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 70,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Psoriasis+Vulgaris&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:59:41.988Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00817219",
      "title": "Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis Vulgaris"
      ],
      "interventions": [
        {
          "name": "Calcipotriene plus betamethasone dipropionate ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LEO Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 33,
      "start_date": "2009-07",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2025-03-12",
      "last_synced_at": "2026-05-21T23:59:41.988Z",
      "location_count": 8,
      "location_summary": "Fremont, California • San Diego, California • Maitland, Florida + 5 more",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Arlington",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00817219"
    },
    {
      "nct_id": "NCT03462927",
      "title": "A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis Vulgaris"
      ],
      "interventions": [
        {
          "name": "MC2-01 Cream",
          "type": "DRUG"
        },
        {
          "name": "CAL/BDP combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MC2 Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2018-02-08",
      "completion_date": "2018-08-04",
      "has_results": true,
      "last_update_posted_date": "2019-12-24",
      "last_synced_at": "2026-05-21T23:59:41.988Z",
      "location_count": 1,
      "location_summary": "Sweetwater, Florida",
      "locations": [
        {
          "city": "Sweetwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03462927"
    },
    {
      "nct_id": "NCT01276639",
      "title": "A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Placebo/CP-690,550",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 901,
      "start_date": "2011-03",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-09-19",
      "last_synced_at": "2026-05-21T23:59:41.988Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Irvine, California • San Diego, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01276639"
    },
    {
      "nct_id": "NCT01999868",
      "title": "Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "UST Placebo",
          "type": "DRUG"
        },
        {
          "name": "ABA Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 108,
      "start_date": "2014-03-19",
      "completion_date": "2018-03-01",
      "has_results": true,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-05-21T23:59:41.988Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01999868"
    },
    {
      "nct_id": "NCT01163253",
      "title": "A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2867,
      "start_date": "2010-09",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2017-06-26",
      "last_synced_at": "2026-05-21T23:59:41.988Z",
      "location_count": 101,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01163253"
    },
    {
      "nct_id": "NCT04633616",
      "title": "Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Psoriasis",
        "Atopic Dermatitis",
        "Acne"
      ],
      "interventions": [
        {
          "name": "Tailored Patient-Provider Communication",
          "type": "OTHER"
        },
        {
          "name": "Non-Tailored Patient-Provider Communication",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2020-11-16",
      "completion_date": "2022-01-19",
      "has_results": false,
      "last_update_posted_date": "2022-12-15",
      "last_synced_at": "2026-05-21T23:59:41.988Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04633616"
    },
    {
      "nct_id": "NCT01636687",
      "title": "Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plaque-type Psoriasis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 150mg",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab 300mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2012-10-17",
      "completion_date": "2016-10-27",
      "has_results": true,
      "last_update_posted_date": "2018-09-27",
      "last_synced_at": "2026-05-21T23:59:41.988Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01636687"
    },
    {
      "nct_id": "NCT03322137",
      "title": "Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pruritus",
        "Psoriasis Vulgaris"
      ],
      "interventions": [
        {
          "name": "SNA-120",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sienna Biopharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2017-10-10",
      "completion_date": "2018-10-22",
      "has_results": false,
      "last_update_posted_date": "2019-02-08",
      "last_synced_at": "2026-05-21T23:59:41.988Z",
      "location_count": 38,
      "location_summary": "Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 35 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03322137"
    },
    {
      "nct_id": "NCT02038569",
      "title": "An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis Vulgaris"
      ],
      "interventions": [
        {
          "name": "LEO 80185 gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LEO Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 125,
      "start_date": "2014-01",
      "completion_date": "2018-02-13",
      "has_results": true,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-05-21T23:59:41.988Z",
      "location_count": 8,
      "location_summary": "San Diego, California • Tampa, Florida • Indianapolis, Indiana + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Forest Hills",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02038569"
    },
    {
      "nct_id": "NCT03668613",
      "title": "Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Chronic Plaque-type Psoriasis"
      ],
      "interventions": [
        {
          "name": "secukinumab low dose",
          "type": "DRUG"
        },
        {
          "name": "secukinumab high dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 84,
      "start_date": "2018-08-29",
      "completion_date": "2023-09-12",
      "has_results": true,
      "last_update_posted_date": "2025-05-16",
      "last_synced_at": "2026-05-21T23:59:41.988Z",
      "location_count": 4,
      "location_summary": "Fountain Valley, California • Jacksonville, Florida • Lebanon, New Hampshire + 1 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03668613"
    }
  ]
}